PDF(Pubmed)
Abstract：
UNASSIGNED: Intra-articular corticosteroid injections (IACI) have been shown to be effective at improving arthritis across juvenile idiopathic arthritis (JIA) categories. The American College of Rheumatology (ACR) recommends IACI use as primary and adjunctive therapy for JIA patients. However, there remains minimal data describing actual IACI use in North America. The objective of this study was to describe and to evaluate IACI use in JIA, utilizing the Pediatric Rheumatology Care and Outcomes Improvement Network (PR-COIN) registry.
UNASSIGNED: Study participants from 13 sites were enrolled in the PR-COIN registry from 2011 to 2015. Demographic and clinical variables were summarized and Chi-squared and t-tests were used to evaluate differences between participants who did or did not receive IACI. Multiple logistic regression models were used to evaluate characteristics associated with IACI treatment.
UNASSIGNED: Our study included 3,241 participants, the majority of whom were white (85%), female (71%) and had oligoarticular JIA (39%). IACI was administered at least once in 23% of participants, the majority of whom had oligoarticular disease (52.5%), but overall use in oligoarticular participants was low at 30.8%. IACI use varied significantly between treatment centers and use was associated with oligoarticular disease, ANA positivity, and use of other systemic medications.
UNASSIGNED: This study demonstrates that participants with JIA enrolled in the PR-COIN registry between 2011 and 2015 with persistent oligoarticular disease, ANA positivity, and use of other systemic medications were more likely to receive IACI. However, IACI use was lower than expected for oligoarticular participants.
UNASSIGNED: Study participants from 13 sites were enrolled in the PR-COIN registry from 2011 to 2015. Demographic and clinical variables were summarized and Chi-squared and t-tests were used to evaluate differences between participants who did or did not receive IACI. Multiple logistic regression models were used to evaluate characteristics associated with IACI treatment.
UNASSIGNED: Our study included 3,241 participants, the majority of whom were white (85%), female (71%) and had oligoarticular JIA (39%). IACI was administered at least once in 23% of participants, the majority of whom had oligoarticular disease (52.5%), but overall use in oligoarticular participants was low at 30.8%. IACI use varied significantly between treatment centers and use was associated with oligoarticular disease, ANA positivity, and use of other systemic medications.
UNASSIGNED: This study demonstrates that participants with JIA enrolled in the PR-COIN registry between 2011 and 2015 with persistent oligoarticular disease, ANA positivity, and use of other systemic medications were more likely to receive IACI. However, IACI use was lower than expected for oligoarticular participants.
摘要：
关节内注射皮质类固醇激素（IACI）已被证明可有效改善幼年特发性关节炎（JIA）类别的关节炎。美国风湿病学会（ACR）建议使用IACI作为JIA患者的主要和辅助治疗。然而,描述北美实际使用IACI的数据仍然很少。这项研究的目的是描述和评估IACI在JIA中的使用，利用儿科风湿病护理和结果改善网络（PR-COIN）注册表。
■从2011年到2015年，来自13个研究中心的研究参与者加入了PR-COIN注册。总结了人口统计学和临床变量，并使用卡方和t检验来评估接受或未接受IACI的参与者之间的差异。使用多元逻辑回归模型来评估与IACI治疗相关的特征。
■我们的研究包括3,241名参与者，其中大多数是白人（85%），女性（71％）和少关节JIA（39％）。23％的参与者至少服用了一次IACI，其中大多数患有少关节疾病（52.5%），但少关节参与者的总体使用率较低,为30.8%.IACI的使用在治疗中心之间差异很大，使用与少关节疾病相关，ANA阳性，和使用其他全身性药物。
■这项研究表明，在2011年至2015年期间，患有JIA的参与者参加了PR-COIN注册，患有持续性少关节疾病，ANA阳性，使用其他全身性药物更有可能接受IACI。然而,少关节参与者的IACI使用率低于预期。
■从2011年到2015年，来自13个研究中心的研究参与者加入了PR-COIN注册。总结了人口统计学和临床变量，并使用卡方和t检验来评估接受或未接受IACI的参与者之间的差异。使用多元逻辑回归模型来评估与IACI治疗相关的特征。
■我们的研究包括3,241名参与者，其中大多数是白人（85%），女性（71％）和少关节JIA（39％）。23％的参与者至少服用了一次IACI，其中大多数患有少关节疾病（52.5%），但少关节参与者的总体使用率较低,为30.8%.IACI的使用在治疗中心之间差异很大，使用与少关节疾病相关，ANA阳性，和使用其他全身性药物。
■这项研究表明，在2011年至2015年期间，患有JIA的参与者参加了PR-COIN注册，患有持续性少关节疾病，ANA阳性，使用其他全身性药物更有可能接受IACI。然而,少关节参与者的IACI使用率低于预期。
